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Abstract Guanosine exerts neuroprotective effects in the
central nervous system. Apoptosis, a morphological form of
programmed cell death, is implicated in the pathophysiology
of Parkinson’s disease (PD). MPP
+, a dopaminergic neuro-
toxin, produces in vivo and in vitro cellular changes
characteristic of PD, such as cytotoxicity, resulting in
apoptosis. Undifferentiated human SH-SY5Y neuroblastoma
cells had been used as an in vitro model of Parkinson’s
disease. We investigated if extracellular guanosine affected
MPP
+-induced cytotoxicity and examined the molecular
mechanisms mediating its effects. Exposure of neuroblasto-
ma cells to MPP
+ (10 μM–5m Mf o r2 4 –72 h) induced DNA
fragmentation in a time-dependent manner (p<0.05). Ad-
ministration of guanosine (100 μM) before, concomitantly
with or, importantly, after the addition of MPP
+ abolished
MPP
+-induced DNA fragmentation. Addition of MPP
+
(500 μM) to cells increased caspase-3 activity over 72 h
(p<0.05), and this was abolished by pre- or co-treatment
with guanosine. Exposure of cells to pertussis toxin prior to
MPP
+ eliminated the anti-apoptotic effect of guanosine,
indicating that this effect is dependent on a Gi protein-
coupled receptor, most likely the putative guanosine recep-
tor. The protection by guanosine was also abolished by the
selective inhibitor of the enzyme PI-3-K/Akt/PKB
(LY294002), confirming that this pathway plays a decisive
role in this effect of guanosine. Neither MPP
+ nor guanosine
had any significant effect on α-synuclein expression. Thus,
guanosine antagonizes and reverses MPP
+-induced cytotox-
icity of neuroblastoma cells via activation of the cell survival
pathway, PI-3-K/Akt/PKB. Our results suggest that guano-
sine may be an effective pharmacological intervention in PD.
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AIF apoptosis-inducing factor
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CREB cAMP response element binding protein
DMSO dimethyl sulfoxide
DTT dithiothreitol
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ELISA enzyme-linked immunosorbent assay
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid
LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-
4–1-hydrochloride]
MAPK mitogen-activated protein kinase
MEK MAP kinase kinase
MPP
+ 1-methyl-4-phenylpyridinium ion
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NF-κB nuclear factor -κB
PD Parkinson’s disease
PD98059 [2-(2-amino-3-methoxyphenyl)-4H-1-
benzopyran-4–1]
PI-3-K phosphatidylinositol-3-OH kinase
PKB protein kinase B
PTX pertussis toxin
ROS reactive oxygen species
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder caused primarily by selective degeneration of
dopaminergic neurons in the substantia nigra pars compacta
[1, 2]. Apoptosis, a morphological form of programmed cell
death [3], has been implicated in the pathophysiology of PD
[4–6]. The biochemical pathways that mediate apoptosis
may be initiated by extrinsic (e.g. activation of the death
receptors) or intrinsic factors (e.g. mitochondrial insult) [7]
and result in the activation of a set of cysteine-dependent
aspartyl proteases (caspases) [8]. Both apoptotic pathways
stimulate the effector enzyme, caspase-3 [7, 9, 10], which in
turn activates a specific nuclear DNAse that degrades DNA
into 200 base pair oligonucleosomal fragments, a hallmark
of apoptosis [11, 12]. Apoptosis-related alterations have been
reported in the dopaminergic brain regions in post-mortem
tissues of PD patients, including increased caspase-3 activity
in the substantia nigra [13, 14], and elevated immunoreac-
tivity of the pro-apoptotic protein, Bax [15], indicating that
apoptosis may play a role in the pathophysiology of PD.
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) has beenused extensively tostudy PD [16, 17].
MPTP selectively targets and damages the dopaminergic
neurons causing parkinsonism in humans and other primates
[18, 19]. MPTP readily crosses the blood-brain barrier and is
converted into the active metabolite, 1-methyl-4-phenyl
pyridinium (MPP
+)[ 17]. MPP
+ is taken up by the
dopaminergic neurons and accumulates in the mitochondria,
where it inhibits complex I of the electron transport chain
and ultimately causes neuronal cell death [5]. The mecha-
nisms of MPP
+-induced cytotoxicity most likely involve
oxidative stress [20]. Several groups reported that treatment
of mice with MPTP induces a Parkinson-like syndrome [16],
accompanied by apoptosis of the dopaminergic neurons in
the substantia nigra [21] and up-regulation of α-synuclein, a
pre-synaptic protein, which plays an important role in PD
pathogenesis [22]. In vitro studies using human SH-SY5Y
neuroblastoma cells have produced comparable results [23,
24]. Exposure of these cells to MPP
+ led to fragmentation of
nuclear DNA [25], activation of caspase-3 [23, 26]a n dt o
up-regulation of α-synuclein [27–29]. In cultured SH-SY5Y
cells dopamine-dependent cytotoxicity was enhanced by the
accumulation of α-synuclein [30]. Therefore, targeting the
molecular pathways activated during apoptosis may lead to
novel treatment strategies for PD [5, 31].
Guanosine and other non-adenine-based purines exert
neuroprotective effects in the central nervous system [32].
In vitro guanosine also protects rat astrocytes from
staurosporine-induced apoptosis [33] and SH-SY5Y cells
from β-amyloid-induced apoptosis [34]. In both cases, the
anti-apoptotic effect of guanosine was mediated by stimu-
lation of the phosphatidylinositol-3-kinase (PI-3-K)/Akt/
protein kinase B (PKB) and mitogen-activated protein
kinase (MAPK) cell survival pathways [33, 34]. These
pathways were activated via the pertussis toxin-sensitive Gi
protein-coupled putative guanosine receptor that we have
recently characterized pharmacologically [35–37].
In PD, symptoms appear only after the majority of the
dopaminergic neurons in the substantia nigra pars compacta
have degenerated, so putative neuroprotective drugs for PD
should be tested in models in which the neurodegenerative
process is already underway [38]. Therefore, we examined
the effects of guanosine on MPP
+-induced caspase-3
activation and DNA fragmentation in SH-SY5Y human
neuroblastoma cells not only when it was added prior to, or
at the same time as MPP
+, but also when it was added to
the cultures up to 48 h after MPP
+ treatment, when the pro-
apoptotic pathways were already activated. We also studied
the molecular mechanisms that mediate the neuroprotective
effects of guanosine.
Materials and methods
Tissue culture and treatment of human SH-SY5Y
neuroblastoma cells
Human SH-SY5Y neuroblastoma cells (ATCC, Manassas,
VA, USA) were cultured using 45% minimum essential
medium, 45% F12 Hamilton’s medium supplemented with
10% fetal bovine serum (FBS), 100 U/ml of penicillin and
1 0 0U / m lo fs t r e p t o m y c i na tap Ho f7 . 4( a l lf r o m
Invitrogen, Burlington, ON, Canada). Culture medium
was changed every 3–4 days, and cells were maintained
in a humidified 5% CO2 atmosphere at 37°C and
subcultured at a ratio of 1:20 every 7–10 days. Culture
400 Purinergic Signalling (2007) 3:399–409medium was changed to 1% FBS for 24 h before the start of
each experiments. All experiments were performed using
70–80% confluent cultures.
Apoptosis was induced by adding MPP
+ (Sigma-Aldrich)
to SH-SY5Y neuroblastoma cells, using a fresh stock solution
of MPP
+ ( 1 0m Mi nr e v e r s eo s m o s i sp u r i f i e dH 2O). In all
experiments, guanosine (Sigma-Aldrich) was dissolved in
0.1 M NaOH and added to the culture medium at a final
concentration of 0.001 M NaOH. Some cells (control) were
exposed to 0.001 M NaOH. In experiments in which the
protective effect of guanosine was tested, guanosine
(100 μM) was added to SH-SY5Y neuroblastoma cells
either: 1 h prior to the administration of MPP
+ (pre-
treatment), or at the same time as MPP
+ (co-treatment) or
24 or 48 h after the addition of MPP
+ (post-treatment at 24 h,
or post-treatment at 48 h, respectively; Fig. 1). Guanosine and
MPP
+ remained in the culture medium for the duration of the
experiment (24, 48 or 72 h). In the first post-treatment
experimental group at 24 h, cells were exposed to MPP
+ for
2 4h ,f o l l o w e db yM P P
+ plus guanosine for an additional
24 h (Fig. 1). In thesecond post-treatment experimental group
at 48 h, cells were treated with MPP
+ f o r4 8h ,f o l l o w e db y
MPP
+ plus guanosine for an additional 24 h (Fig. 1).
In experiments in which enzyme inhibitors were tested,
SH-SY5Y cells were pre-treated with various agents for
20 min prior to the addition of guanosine. These treatments
included: the potent and selective inhibitor of PI-3-K, [2-(4-
morpholinyl)-8-phenyl-1(4H)-benzopyran-4-1-hydrochlo-
ride] (LY294002; IC50=1.4 μM; Sigma), or the selective
inhibitor of MAP kinase kinase (MEK), [2-(2-amino-3-
methoxyphenyl)-4H-1-benzopyran-4-1] (PD98059; IC50=
2 μM; Sigma). In experiments using the ADP-ribosylating
factor of the inhibitory guanosine nucleotide binding protein
(Gi), pertussis toxin [PTX, 200 ng/ml; in 50% glycerol,
0.5 M NaCl, and 0.05 M Tris-glycine (pH 7.5); Sigma] was
added overnight (16 h). LY294002 and PD98059 were
dissolved in and added to the culture medium at a final
concentration of 0.01% dimethyl sulfoxide (DMSO).
Evaluation of cell death and DNA fragmentation
In initial experiments, cell death was determined using
acridine orange-ethidium bromide (AO-EB, Sigma-Aldrich)
staining. Cells were seeded onto 6-well plates (diameter
10 mm; 2.5×10
4 cells/well) and exposed to MPP
+. After
24, 48 or 72 h, cells were washed three times with
phosphate-buffered saline (PBS) and AO-EB solution
(6 μM/ml) was added to the wells. Cells were examined
using a fluorescence microscope (Nikon, Tokyo, Japan).
The number of fragmented nuclei and/or condensed
chromatin was determined by counting >200 cells. The
percentage of apoptotic cells is defined as: (total number of
cells with apoptotic nuclei/total number of cells) × 100.
In subsequent experiments, DNA fragmentation was
evaluated by the oligonucleosomal ELISA (Cell Death
Detection ELISA
PLUS; Roche Diagnostics, Laval, QC,
Canada) and carried out according to the manufacturer’s
instructions. This assay measures the amount of oligonu-
cleosomal fragments and is a marker of apoptosis [39].
Cells were exposed to MPP
+ alone, or in combination with
guanosine or pre-treated with the various inhibitors as
described above. Following various treatments, cells were
isolated for analysis of DNA fragmentation as described by
Pettifer et al. [34]. For the oligonucleosomal ELISA,
10,000 viable cells/treatment were lysed and centrifuged
(200 g for 10 min) to isolate fragmented oligonucleosomal
DNA. The cytosolic fractions of cell lysates were trans-
ferred into streptavidin-coated microplate wells, and a
mixture of biotin-linked anti-histone antibody and peroxi-
dase-linked anti-DNA antibody was added and incubated
for 2 h at room temperature. Plates were washed with
incubation buffer to remove the unfixed anti-DNA antibody
and the peroxidase activity was determined spectrophoto-
metrically with 2,2′-azino-bis[3-ethylbenzthiazoline-6-sul-
fonic acid] (ABTS) as the substrate (absorbance of
405 nm). The amount of DNA fragmentation is expressed
as a percentage of the positive control provided with the kit.
Determination of caspase-3 activity
Caspase-3 activity was determined using the caspase-3
colourimetric assay (Sigma-Aldrich). Cells were exposed to
Fig. 1 Experimental design for guanosine post-treatment of SH-
SY5Y neuroblastoma cells added at 24 or 48 h after MPP
+. SH-SY5Y
neuroblastoma cells were exposed to either vehicle, or guanosine
(100 μM) or MPP
+ (500 μM) for various times. For post-treatment
experiments with guanosine at 24 h, cells were exposed to MPP
+ for
24 h, followed by MPP
+ plus guanosine for an additional 24 h (total
MPP
+ exposure = 48 h). For post-treatment experiments with
guanosine at 48 h, cells were exposed to MPP
+ for 48 h followed by
MPP
+ plus guanosine for a further 24 h (total MPP
+ exposure = 72 h).
Once added, guanosine and MPP
+ remained in the culture medium for
the duration of the experiment. DNA fragmentation, or caspase-3
activity, was determined at 24, 48 or 72 h as described in the
“Materials and methods” section
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isolated, re-suspended in 100 μl/10
7 cells of lysis buffer
(50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), pH 7.4, 5 mM 3[(3-cholamidopropyl)
dimethylammonio]-propanesulfonic acid (CHAPS), 5 mM
dithiothreitol (DTT)) and incubated on ice for 20 min. Cell
lysates were centrifuged (18,000 g for 10 min at 4°C) and
the supernatants (5 μl/well) were transferred to 96-well
plates. A selective caspase-3 inhibitor (N-acetyl-Asp-Glu-
Val-Asp-CHO; 10 μl/well at 200 μM) was added to
supernatants to control for the nonspecific hydrolysis of
the substrate. Purified caspase-3 human recombinant
protein, provided with the assay, was used (5 μl/well at
5 μg/ml) as a positive control for caspase-3 activity. Cell
lysates were incubated in an assay buffer [40 mM HEPES,
pH 7.4, 1% CHAPS, 10 mM DTT, 4 mM ethylenediami-
netetraacetic acid (EDTA)], containing N-acetyl-Asp-Glu-
Val-Asp p-nitroaniline (10 μl/well at 2 mM) overnight at
37°C and the formation of p-nitroaniline was measured at
405 nm, using a microtiter plate reader. The activity of
caspase-3 was calculated from the absorbance values using
a calibration curve, and it is expressed as μg of substrate
cleaved/min per ml. As the number of cells in 1 ml of cell
lysate is adjusted to 1×10
8 cells, this caspase-3 activity is
generated by 1×10
8 cells.
Measurement of α-synuclein protein concentration
by ELISA
The concentration of α-synuclein protein in SH-SY5Y
neuroblastoma cells was determined by an ELISA (Bio-
Source, San Diego, CA, USA). Cells were exposed to various
treatments as described above and subsequently lysed using a
cell extraction buffer (10 mM Tris, pH 7.4, 100 mM NaCl,
1m ME D T A ,1m MN a F ,2 0m MN a 4P2O7, 2 mM Na3VO4,
1% Triton X-100, 10% glycerol, 0.1% sodium dodecyl
sulfate, 0.5% deoxycholate; BioSource, San Diego, CA,
USA), containing protease inhibitors [1 mM phenylmetha-
nesulfonyl fluoride, 2 mM 4-(2-aminoethyl) benzenesulfonyl
fluoride, 130 μMb e s t a t i n ,1 4μM E-64, 1 μMl e u p e p t i n ,
0.3 μM aprotinin; Sigma]. Cells were incubated on ice in
cell extraction buffer for 30 min and centrifuged (14,000 g
for 10 min at 4°C). Aliquots of supernatants (25 μl) were
removed for the determination of the total protein concen-
tration using the bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL, USA). We measured α-synuclein
protein concentration using an ELISA kit according to the
manufacturer’s instructions. Briefly, cell lysates (diluted
1:10) were added to α-synuclein antibody-coated wells in
duplicate, allowed to bind and then were treated with the
anti-α-synuclein antibody. This was followed by the addition
of an anti-rabbit IgG-horse radish peroxidase-linked anti-
body, and by the addition of a stabilized chromogen
(tetramethylbenzidine). The reaction was terminated by
adding 1 M HCl (stop solution) provided with the kit, and
the absorbance of each well was read at 450 nm. Standard
curves were prepared using purified recombinant α-synu-
clein protein (100 ng/ml) provided with the kit. The
concentration of the α-synuclein protein in each sample
was determined from a nonlinear regression, and it is
expressed as a ratio of α-synuclein protein (in ng/ml) to
total protein concentration (in ng/ml).
Statistical analysis
Data obtained in experiments testing the concentration
dependence of the protective effect of guanosine on MPP
+-
induced DNA fragmentation (Fig. 3) and the effect of PTX,
and inhibitors of the PI-3-K, and the MAPK pathways on
DNA fragmentation (Fig. 6 and Table 1) were analyzed by
a one-way analysis of variance (ANOVA) followed by a
Student-Newman-Keul post-hoc test. Two-way ANOVA,
followed by a Bonferroni post-hoc test, was used to analyze
the data obtained from experiments evaluating the effects of
guanosine, administered at different time points on MPP
+-
induced DNA fragmentation (Fig. 4) and on MPP
+-induced
caspase-3 activation (Fig. 5). A p v a l u eo f0 . 0 5o rl e s sw a s
considered statistically significant. Results represent the
mean ± SEM of a minimum of three independent experiments.
Results
MPP
+ induces DNA fragmentation in SH-SY5Y
neuroblastoma cells
SH-SY5Y neuroblastoma cells were exposed to different
concentrations of MPP
+ (10–500 μM) for various times (0–
72 h) to optimize the experimental conditions and to
confirm that MPP
+-induced DNA fragmentation was
concentration and time dependent (Fig. 2). DNA fragmen-
tation in untreated control cells was around 10% and
remained unchanged for up to 72 h (Fig. 2). Treatment of
cells with 500 μM MPP
+ increased DNA fragmentation
significantly after 48 h (p<0.01) and 72 h (p<0.001; Fig. 2)
compared to untreated controls. Since exposure of cells to
500 μM MPP
+ for 48 h induced robust DNA fragmenta-
tion, these conditions were used in the following studies.
Pre-treatment of SH-SY5Y neuroblastoma cells
with guanosine attenuates MPP
+-induced DNA
fragmentation
SH-SY5Y cells were exposed to various concentrations of
guanosine (1–300 μM) for 1 h, followed by the addition of
500 μM MPP
+ for a further 48 h, and DNA fragmentation
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observed in the previous experiment the addition of MPP
+
(500 μM) led to significantly increased DNA fragmentation
compared to controls (p<0.001; Fig. 3). Pre-treatment of
cells for 1 h with various concentrations of guanosine (10–
300 μM) significantly reduced MPP
+-induced DNA frag-
mentation (p<0.05) for all four concentrations of guanosine
compared to cells treated with MPP
+ alone (Fig. 3). Based
on these results, we used 100 μMg u a n o s i n ei na l l
subsequent experiments.
Post-treatment with guanosine protects SH-SY5Y
neuroblastoma cells against MPP
+-induced DNA
fragmentation
We next examined whether guanosine exerted any effect on
MPP
+-induced DNA fragmentation when it was added to
neuroblastoma cells after apoptosis was already in progress.
Cells were pre-treated with 100 μM guanosine prior to
MPP
+ or co-treated with guanosine plus MPP
+ or, as
described in Fig. 1, guanosine was added as post-treatment.
DNA fragmentation was determined in cells exposed to
various treatments after 24, 48 and 72 h of MPP
+
administration (Fig. 4). The addition of MPP
+ led to a
significant increase in DNA fragmentation compared to
controls at 48 h (p<0.01) and 72 h (p<0.001) (Fig. 4).
Guanosine alone had no significant effect on DNA
fragmentation (Fig. 4). Pre-treatment of cells with guano-
sine significantly reduced DNA fragmentation after 48 and
72 h compared to MPP
+ treatment alone, at the respective
time points (p<0.05, at both time points; Fig. 4). Similarly,
co-treatment of cells with guanosine plus MPP
+ signifi-
cantly reduced DNA fragmentation after 48 and 72 h
compared to cells treated with MPP
+ alone at these times
(p<0.05, at both time points; Fig. 4). Addition of guanosine
24 h after MPP
+ (post-treatment at 24 h) or 48 h after
MPP
+ (post-treatment at 48 h) reduced DNA fragmentation
significantly compared to cells treated with MPP
+ alone for
48 or 72 h, respectively (p<0.05, for both treatments;
Fig. 4). These results demonstrate that pre-treatment or co-
treatment of cells with guanosine and MPP
+ attenuates
MPP
+-induced DNA fragmentation, and guanosine added
24 or 48 h after the start of the DNA fragmentation (post-
treatment) can actually reverse this process.
Guanosine inhibits MPP
+-induced caspase-3 activity
Exposure of SH-SY5Y cells to MPP
+ leads to apoptosis via
caspase-3 activation [23, 26]. We therefore examined if
under our experimental conditions treatment of neuroblas-
toma cells with MPP
+ activated caspase-3 and whether the
addition of guanosine to MPP
+-treated cells at various times
(pre-treatment, co-treatment or post-treatment) had any
effect on the activity of this enzyme. In untreated control
cells caspase-3 activity was low and remained unchanged
for up to 72 h (Fig. 5). Addition of guanosine to cells had
no significant effect on caspase-3 activity (Fig. 5). In
MPP
+-treated cells caspase-3 activity increased significant-
ly from 24 to 72 h (p<0.001, at all time points; Fig. 5). Pre-
treatment of cells with guanosine prior to MPP
+ addition
significantly reduced caspase-3 activity after 48 or 72 h
compared to that in cells treated with MPP
+ alone for the
same time (p<0.01, at both time points; Fig. 5). Similar
results were also obtained when cells were co-treated with
Fig. 2 MPP
+ induces DNA fragmentation in SH-SY5Y cells. MPP
+
(10, 100 or 500 μM) was added to SH-SY5Y cells and DNA
fragmentation determined after 24, 48 or 72 h by oligonucleosomal
ELISA as described in the “Materials and methods” section. Data are
presented as the percentage of DNA fragmentation relative to a
positive control (n>3). MPP
+ (500 μM) increased DNA fragmentation
significantly at 48 h (*p<0.01) and at 72 h (**p<0.001) compared to
that of untreated cells at zero time
Fig. 3 Pre-treatment of SH-SY5Y cells with guanosine decreases
MPP
+-induced DNA fragmentation. SH-SY5Y cells were exposed to
MPP
+ (500 μM) for 48 h to induce DNA fragmentation. Some cells
were pre-treated with guanosine (1–300 μM) for 1 h prior to MPP
+.
Guanosine and MPP
+ remained in the cultures for the duration of the
experiment. DNA fragmentation was determined after 48 h by
oligonucleosomal ELISA as described in the “Materials and methods”
section and is expressed as the percentage of the positive control (n>
3). MPP
+ increased DNA fragmentation significantly at 48 h compared
to that of untreated controls (*p<0.001). Pre-treatment with guanosine
(10–300 μM) reduced significantly the MPP
+-induced DNA fragmen-
tation compared to that in cells treated with MPP
+ for the same time
(#p<0.05, at all four concentrations)
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+ for 48 and 72 h (p<0.01, at both time
points; Fig. 5). Post-treatment with guanosine at 24 h (see
Fig. 1) also reduced caspase-3 activity significantly at 48 h
compared to that in cells treated with MPP
+ alone at this
time point (p<0.01; Fig. 5). When guanosine was added to
cells 48 h after the addition of MPP
+ (post-treatment at
48 h), caspase-3 activity determined after 72 h was
unaffected compared to MPP
+ treatment alone at this time
point (Fig. 5). These results thus demonstrate that pre-
treatment, co-treatment or post-treatment at 24 h of
neuroblastoma cells with guanosine prevents MPP
+-in-
duced activation of caspase-3. Administration of guanosine
to cells 48 h after MPP
+ however has no effect on caspase-3
activity.
Guanosine has no effect on α-synuclein protein expression
in MPP
+-treated neuroblastoma cells
Several authors reported that addition of MPP
+ to SH-
SY5Y cells increased α-synuclein protein expression [27,
29]. We therefore determined α-synuclein protein concen-
tration in neuroblastoma cells under our experimental
conditions (500 μM MPP
+ for 48 h) and evaluated the
effects of guanosine on the expression of this protein in
MPP
+-treated cells. The ratio of α-synuclein protein/total
protein in untreated control cells after 48 h was very low
and exposure of neuroblastoma cells to MPP
+ for 48 h had
no significant effect on the expression of this protein (data
not shown). Treatment of cells with guanosine prior to the
addition of MPP
+, or at the same time as MPP
+ or 24 h after
MPP
+ had no significant effect on of α-synuclein protein
expression (data not shown). These results indicate that
under the present experimental conditions neither MPP
+ nor
a combination of guanosine plus MPP
+ has any effect on α-
synuclein protein expression.
Fig. 4 Guanosine antagonizes and reverses MPP
+-induced DNA fragmentation in SH-SY5Y cells. SH-SY5Y cells were exposed to MPP
+
(500 μM) for 48 h to induce DNA fragmentation. Some cells were treated with guanosine (100 μM) either for 1 h prior to MPP
+ (pre-treatment),
or at the same time as MPP
+ (co-treatment) or 24 or 48 h after MPP
+ (post-treatment, see Fig. 1). DNA fragmentation was determined after 24, 48
or 72 h of MPP
+ addition by oligonucleosomal ELISA as described in the “Materials and methods” section and it is expressed as a percentage of
the positive control (n>3). MPP
+ induced a significant increase in DNA fragmentation at 48 (*p<0.01) and at 72 h (**p<0.001) compared to that
of untreated control cells at the same time. Pre-treatment or co-treatment of cells with guanosine significantly reduced MPP
+-induced DNA
fragmentation at 48 and 72 h compared to that in cells treated with MPP
+ alone at the same time (#p<0.05 at both time points, for both
treatments). Post-treatment with guanosine at 24 or 48 h also reduced MPP
+-induced DNA fragmentation at 48 and 72 h compared to that in cells
treated with MPP
+ alone at the same time (#p<0.05, at both time points)
Fig. 5 Guanosine inhibits MPP
+-induced caspase-3 activation in SH-
SY5Y cells. SH-SY5Y cells were exposed to MPP
+ (500 μM) for 48 h
to induce to induce caspase-3 activation. Some cells were treated with
guanosine (100 μM) either for 1 h prior to MPP
+ (pre-treatment), or at
the same time as MPP
+ (co-treatment) or 24 or 48 h after MPP
+ (post-
treatment, see Fig. 1). Caspase-3 activity was determined as described
in the “Materials and methods” section and is expressed as the amount
of N-acetyl-Asp-Glu-Val-Asp p-nitroaniline cleaved by 1×10
8 cells, in
μg/min per ml (n>3). MPP
+ significantly increased caspase-3 activity
from 24 to 72 h (*p<0.001, at all three time points) compared to that
of control cells at the same time. Pre-treatment or co-treatment of cells
with guanosine significantly reduced MPP
+-induced caspase-3 activ-
ity, at 48 and 72 h, compared to that in cells treated with MPP
+ alone
at the same time (#p<0.01, at both time points, for both treatments).
Post-treatment with guanosine at 24 h reduced MPP
+-induced
caspase-3 activity at 48 h compared to that in cells treated with
MPP
+ alone at the same time (#p<0.01). Guanosine added to cultures
48 h after MPP
+ had no effect on caspase-3 activity
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We reported recently that specific binding sites exist for
guanosine in rat brain membranes [35], in cultured rat
astrocytes [36] and in SH-SY5Y neuroblastoma cells
(Traversa and Caciagli, 2005, personal communications).
We have further shown that guanosine binding in these
cells is sensitive to treatment with PTX [37, 40], indicating
that the putative guanosine receptor is coupled to Gi
protein. We therefore tested whether the anti-apoptotic
effect of guanosine in the MPP
+-treated cells is mediated
via this putative guanosine receptor. Cells were exposed to
PTX (200 ng/ml for 16 h) prior to the various treatments
with guanosine and MPP
+ (pre-treatment, co-treatment or
post-treatment at 24 h) and DNA fragmentation was
determined at 48 h. As in previous experiments, MPP
+
induced a significant increase in DNA fragmentation and
the addition of guanosine alone had no significant effect on
this process (Fig. 6). Exposure of neuroblastoma cells to
PTX alone increased DNA fragmentation slightly under
basal conditions, but this was not statistically significant.
Pre-treatment, co-treatment or post-treatment at 24 h of
cells with guanosine and MPP
+ significantly reduced DNA
fragmentation compared to cells treated with MPP
+ only
(p<0.01, for all three treatments; Fig. 6). Addition of PTX
to neuroblastoma cells prior to any of the three guanosine
plus MPP
+ treatments reversed the anti-apoptotic effect of
guanosine (Fig. 6). These results demonstrate that regard-
less of the time of its addition to MPP
+-treated cells, the
protective effect of guanosine is abolished by PTX. These
findings are consistent with the interpretation that these
effects are mediated by a Gi protein-coupled receptor, most
likely the putative guanosine receptor.
Guanosine protects against MPP
+-induced apoptosis
by activating the cell survival pathways
We have shown earlier that guanosine activates the PI-3-K/
Akt/PKB and MAPK pathways in neuroblastoma cells [34].
We therefore evaluated if the protective effects of guanosine
against MPP
+-induced DNA fragmentation were also
mediated via these signaling pathways. Cells were exposed
to either LY294002, or to PD98059, selective inhibitors of
PI-3-K or MEK, respectively, for 20 min prior to various
treatments with guanosine and MPP
+ (pre-treatment, co-
treatment or post-treatment at 24 h). Exposure of neuro-
blastoma cells to LY294002 alone had no significant effect
on DNA fragmentation under basal conditions. Although in
cells exposed to PD98059 alone DNA fragmentation
increased slightly, this was not statistically significant
(Table 1). As in previous experiments, the addition of
MPP
+ induced significant DNA fragmentation and treat-
Fig. 6 Pertussis toxin abolishes the anti-apoptotic effect of guanosine
in SH-SY5Y cells. SH-SY5Y cells were exposed to MPP
+ (500 μM)
for 48 h to induce DNA fragmentation. Some cells were treated with
guanosine (100 μM) either for 1 h prior to MPP
+ (pre-treatment), or at
the same time as MPP
+ (co-treatment) or 24 h after MPP
+ (post-
treatment, see Fig. 1). Pertussis toxin (PTX, 200 ng/ml for 16 h) was
added to some cultures prior to pre-treatment or co-treatment or post-
treatment with guanosine at 24 h. DNA fragmentation was determined
at 48 h and is expressed as a percentage of the positive control (n>3).
MPP
+ increased DNA fragmentation significantly at 48 h (*p<0.001)
compared to that of untreated control cells at the same time. Pre-
treatment, or co-treatment or post-treatment of cells with guanosine at
24 h reduced significantly MPP
+-induced DNA fragmentation
compared to that in cells treated with MPP
+ alone at the same time
(
§p<0.01). PTX reversed the protective effect of guanosine. DNA
fragmentation in cells exposed to PTX plus pre-treatment,o rco-
treatment or post-treatment with guanosine was significantly higher
compared to that of cells without PTX (
#p<0.05, for all three
treatments). These values were comparable to that obtained in cells
treated with MPP
+ alone
Table 1 Effect of selected inhibitors of cell survival pathways on the
anti-apoptotic effect of guanosine in SH-SY5Y cells
Treatment DNA fragmentation (% of positive control)
No inhibitor LY294002
10 μM
PD98059
10 μM
Control 10.1±1.3 16.3±3.1 24.0±4.7
MPP
+ (500 μM) 34.5±4.3
a ––
Guanosine pre-treatment 15.9±4.8 38.6±10.3
b 38.3±9.1
b
Guanosine co-treatment 11.0±0.7 32.9±5.7
b 28.7±10.4
n.s.
Guanosine post-treatment 12.4±1.8 48.2±4.3
c 28.4±4.8
n.s.
SH-SY5Y cells were exposed to MPP
+ (500 μM) for 48 h to induce
DNA fragmentation. Some cells were treated with guanosine (100 μM)
either for 1 h prior to MPP
+ (pre-treatment), or at the same time as
MPP
+ (co-treatment) or 24 h after MPP
+ (post-treatment, see Fig. 1).
Some cultures were exposed to LY294002 (inhibitor of PI-3-K) or to
PD98059 (inhibitor of MAP kinase kinase, MEK) for 20 min prior to
the addition of guanosine. DNA fragmentation was determined at 48 h
(n=3) and is expressed as a percentage of the positive control.
LY294002 abolished the protective effect of guanosine in cells pre-
treated, co-treated or post-treated with this nucleoside. PD98059 also
abolished the protective effect of guanosine in cells pre-treated with this
nucleoside, but had no significant effect in cells co-treated or post-
treated with guanosine
ap<0.001 compared to control
bp<0.01 compared to same treatment without inhibitor
cp<0.05 compared to same treatment without inhibitor
n.s.not significant
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significantly reduced DNA fragmentation compared to cells
treated with guanosine (Table 1).
Exposure of cells to LY294002 prior to pre-treatment, or
co-treatment or post-treatment at 24 h with guanosine and
MPP
+ reversed the protective effect of guanosine. DNA
fragmentation in cells exposed to LY294002 plus guanosine
plus MPP
+ was significantly reduced compared to cells
treated with guanosine plus MPP
+ without the inhibitor
(p<0.05, for pre-treatment and co-treatment; p<0.01, for
post-treatment at 24 h; Table 1). Addition of PD98059 to
cells before pre-treatment with guanosine and MPP
+ also
abolished the protective effect of guanosine (p<0.05;
Table 1). But this inhibitor had no significant effect on
MPP
+-induced DNA fragmentation in cells co-treated or
post-treated at 24 with guanosine and MPP
+ (Table 1).
These results demonstrate that the protective effects of
guanosine are abolished by LY294002 in MPP
+-treated cells
regardless of the time of its administration and are consistent
with a role of the PI-3-K/Akt/PKB cell survival pathway in
guanosine-mediated reduction of DNA fragmentation. In
contrast, the effect of PD98059 is limited to pre-treatment of
cells with guanosine prior to MPP
+, thus indicating that the
MAPK pathway contributes to the protective effects of
guanosine only when it is added before MPP
+.
Discussion
We have shown earlier that pre-treatment with guanosine
protects different cell types against apoptosis [33, 34].
Here, we report that guanosine not only protects human
SH-SY5Y neuroblastoma cells against MPP
+-induced apo-
ptosis, but more importantly, it can reverse MPP
+-induced
cytotoxicity after the pro-apoptotic pathways have already
been activated. Thus, these findings are novel and demon-
strate for the first time that guanosine can in fact ‘rescue’
neuroblastoma cells from apoptosis when it is added to cells
under experimental conditions that are ‘clinically relevant’
to the treatment of PD.
Undifferentiated dopaminergic human SH-SY5Y neuro-
blastoma cells have been used widely to study the
molecular pathways that mediate MPP
+-induced apoptosis
[23–29]. MPTP, after conversion to MPP
+, activates the
same intracellular pathways in vivo and in vitro as in
idiopathic PD [2]. Thus, MPP
+ is taken up by dopaminergic
neurons, where it inhibits complex I of the mitochondrial
electron transport chain. This leads to enhanced production
of reactive oxygen species (ROS) and decreased synthesis
of ATP [2]. Prolonged exposure to MPP
+ results in the up-
regulation of the pro-apoptotic protein Bax, and following
its translocation to the mitochondria it promotes the release
of mitochondrial cytochrome c. This may be initiated by the
DNA damage caused by MPP
+. Cytochrome c, together
with pro-caspase-9, is incorporated into the complex, the
apoptosome, which activates caspase-9, and this enzyme in
turn activates caspase-3 [2, 41]. At the same time, the anti-
apoptotic protein, Bcl-2, is down-regulated [42]. Taken
together these data demonstrate that exposure of dopami-
nergic cells to MPP
+ leads to cytotoxicity and cell death by
apoptosis [2, 17]. Our findings are consistent with previous
reports that MPP
+ induces DNA fragmentation and activa-
tion of caspase-3 in SH-SY5Y cells [23, 25]. Interestingly,
we detected no significant change in α-synuclein protein
expression in MPP
+-treated cells (data not shown). This
may be the result of the relatively low MPP
+ concentration
(500 μM) and short duration of our experiments (48 h).
Others reported that high concentrations of MPP
+ (5 mM
for 12 h [29]) or prolonged exposure of neuroblastoma cells
to lower concentrations of MPP
+ (5 μM for 4 days [28]o r
1 mM for 3 days [27]) actually increased α-synuclein
protein concentration. Mutations of this protein have been
associated with a familial form of PD [43] and the wild-
type protein is a major constituent of Lewy bodies [44]. In
MPTP-treated mice α-synuclein expression is up-regulated
[45], and in SH-SY5Y cells accumulation of this protein
contributes to dopamine-dependent apoptosis [30]. Under
our experimental conditions that were optimized to detect
DNA fragmentation, we observed no change in α-synuclein
protein expression.
The molecular mechanisms by which guanosine exerts
its protective effects are complex. Results from the present
study show that the effects of both pre-treatment and co-
treatment with guanosine are pertussis toxin sensitive, and
these may depend on the putative plasma membrane
localized guanosine receptor [35–37] that is coupled to Gi
proteins. There may be other possible explanations, which
account for the effects of pertussis toxin on MPP
+-induced
DNA fragmentation. Since pertussis toxin enters cells and
ADP-ribosylates the α-subunit of Gi proteins [46, 47], it
may also attenuate signaling by other Gi protein-coupled
receptors, resulting in the elevation of intracellular cAMP
[48, 49] and this in turn may activate cell survival
pathways, such as the MAPK [56]. Guanosine may also
enter neuroblastoma cells via the equilibrative or the
concentrative nucleoside transporters [50], cause an alter-
ation in intracellular concentrations of guanine nucleotides
[40] and this in turn may affect G protein activity.
However, as we have shown before, guanosine binding
to its cognate receptor leads to rapid activation of the cell
survival pathways, PI-3-K/Akt/PKB and MAPK [33, 34],
and these play a critical role in protecting neurons against
cell death [51–56]. Although these signaling pathways are
most often triggered by growth factor binding to their
cognate receptors, G protein-coupled receptors have also
been shown to activate them [57–60]. Thus, binding of
406 Purinergic Signalling (2007) 3:399–409guanosine to its Gi protein-coupled putative receptor may
activate the class IB PI-3-K (PI-3-Kγ), via the dissociated
β,γ-subunits of Gi proteins, which promote the synthesis of
phosphatidylinositol (3,4,5) trisphosphate at the plasma
membrane and recruit the protein kinase, Akt/PKB [60, 61].
Activation of Akt/PKB by phosphorylation at Thr 308 and
Ser 473 regulates cell survival and apoptosis by both
transcription-dependent and transcription-independent path-
ways [7, 54, 61]. Thus, Akt/PKB may suppress apoptosis
by phosphorylating and inactivating the pro-apoptotic
protein Bad [62], inhibiting the release of mitochondrial
cytochrome c [63] and inhibiting the activation of caspase-9
and caspase-3 [64]. Expression of cell survival genes may
also be triggered by the PI-3-K/Akt/PKB pathway, via
activation of the transcription factors CREB and NF-κB,
and inhibition of Forkhead transcription factors of the
FOXO family [54].
Similarly, activation of the MAPK pathway, specifically
the extracellular signal-regulated kinases 1 and 2 (ERK1/2),
also prevent apoptosis and promote cell survival by both
transcription-dependent and transcription-independent path-
ways[55, 56, 65, 66]. The specific downstream targets of the
ERK1/2 pathway include inhibition of caspase-9 by phos-
phorylation [67], suppression of the pro-apoptotic protein
Bad by phosphorylation and activation of the transcription
factor CREB [55]. Guanosine binding to its putative receptor
may also stimulate this pathway via the dissociated β,γ-
subunits of Gi proteins [59]. Reports suggest that the PI-3-K/
Akt/PKB and MAPK pathways do not function indepen-
dently, but there is significant cross-talk between them [57,
68]. It has been suggested that whereas the PI-3-K/Akt/PKB
pathway is the main signaling pathway for maintaining
trophic support by pro-survival factors, ERK1/2 mediates
protection against damage-induced cell death [56]. Our
results are thus consistent with the interpretation that
protection of cells from MPP
+-induced DNA fragmentation
by guanosine pre-treatment is dependent on the activation of
both these pathways. Following co-treatment with guanosine
and MPP
+, however, it is the PI-3-K/Akt/PKB pathway,
which plays the essential role.
In the present study, we also examined the effect of
guanosine on MPP
+-induced DNA fragmentation by ex-
posing cells to guanosine after caspase-3 activity was
elevated and DNA fragmentation was already underway
(post-treatment). This strategy is novel and is based on a
recent proposal by Meissner et al. [38], who advocate that
potential neuroprotective agents for the treatment of PD
should be tested under conditions that are relevant to the
clinical situation. Because clinical symptoms of PD are
apparent only after the majority of nigrostriatal neurons
have died, patients do not present for treatment until after
the process of cell death is well established [38]. Most in
vitro studies have been conducted by adding potential
neuroprotective agents to cells prior to MPP
+-triggered
apoptosis [69–71] or at the same time as MPP
+ [27, 72, 73],
making these results irrelevant to the treatment of PD,
where the process of neurodegeneration has already begun.
Addition of guanosine to cells after MPP
+-induced DNA
fragmentation is already in progress may involve additional
protective mechanisms. As DNA fragmentation is a late
event in apoptosis [11, 12], some cells with damaged DNA
may actually undergo DNA repair and survive [74, 75]. The
preferred survival strategy of a cell is to attempt to restore
any DNA damage by using a complex set of DNA repair
pathways [74]. Only when the damage to the DNA
becomes excessive and the repair capacity of the cell is
overwhelmed will it undergo apoptosis. Therefore, adding
guanosine 24 or 48 h after DNA fragmentation has been
initiated may activate some of the DNA repair mechanisms,
antagonizing and reversing the MPP
+-induced DNA frag-
mentation. The protective effects of guanosine in these cells
thus may include activation of both cell survival and DNA
repair pathways.
In contrast, post-treatment with guanosine had no
significant effect on MPP
+-induced activation of caspase-
3. As activation of this enzyme requires a cleavage of the
interdomain region of the inactive dimer of caspase-3, once
this process is initiated it cannot be reversed [8–10]. So
addition of guanosine to cells after proteolytic cleavage of
this enzyme will not alter caspase-3 activity.
Recently administration of MPTP to mice has been
reported to promote caspase-independent cell death of
dopaminergic neurons [76]. This “apoptosis-like”
programmed cell death [77] is mediated by the release of
the apoptosis-inducing factor (AIF) from the mitochondria
and its subsequent translocation to the nucleus, where it
induces DNA fragmentation [78–80]. If this process plays a
significant role inMPP
+-induced cell death of neuroblastoma
cells, DNA fragmentation will still be reversed by the
protective action of guanosine, but caspase-3 activation will
not be affected.
Several authors suggested recently that targeting
programmed cell death in neurodegenerative diseases may
lead to successful therapy [5, 31]. Drugs that will be
effective in PD should protect the dopaminergic cells from
apoptotic insult by either interrupting the signaling path-
ways that mediate cell death or activating the cell survival
pathways. Our present results show that the non-adenine-
based purine nucleoside guanosine, when added to MPP
+-
treated neuroblastoma cells, promotes their survival by
inhibiting caspase-3 activation and DNA fragmentation via
activation of the PI-3-K/Akt/PKB pathway. Furthermore,
guanosine exerts these effects not only when it is pre- or co-
administered with MPP
+, but even when it is added to cells
after caspase-3 is activated and DNA fragmentation is
already in progress. Thus, these findings reveal a unique
Purinergic Signalling (2007) 3:399–409 407neuroprotective effect of guanosine with a potential for
effective pharmacological intervention in PD.
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